uniQure to Build Therapy Production Plant in US to Leverage AAV Manufacturing Strength - - BioPharm International

ADVERTISEMENT

uniQure to Build Therapy Production Plant in US to Leverage AAV Manufacturing Strength



uniQure B.V. has announced it has commenced build-out of a 55,000 ft2  US manufacturing plant in Lexington, Mass., for the production of commercial grade Adeno Associated Virus (AAV)-based gene therapy products to complement its current EMA-approved site in Amsterdam, the Netherlands. The company expects the facility to be operational by early 2015.

The US site will expand the company's current production capacity. Once completed, it is expected to allow uniQure to capitalize on its modular manufacturing platform and leverage its process leadership in commercial grade AAV manufacturing, the company reports.

Source: uniQure
blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
USP Center in Ghana Receives International Lab Accreditation
August 15, 2014
USP Awards Analytical Research
August 15, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
Author Guidelines

Click here